<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645983</url>
  </required_header>
  <id_info>
    <org_study_id>R21AT001916</org_study_id>
    <secondary_id>R21AT001916</secondary_id>
    <nct_id>NCT00645983</nct_id>
  </id_info>
  <brief_title>Chamomile Therapy for Generalized Anxiety</brief_title>
  <official_title>Chamomile Therapy for Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of chamomile extract for treating generalized
      anxiety disorder.

      Study hypotheses: 1)Chamomile extract will have a superior anti-anxiety effect compared to
      placebo. 2)Chamomile will have a comparable safety profile to that of placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to investigate the anti-anxiety activity of Chamomile. Among the many uses of
      Chamomile, its use as an anti-anxiety herb is universal. Despite its widespread use and
      acceptance, there have been no studies evaluating the safety and anti-anxiety efficacy of
      Chamomile in human subjects. Given this lack of controlled clinical data, we propose a pilot
      study of Chamomile safety and efficacy in mild anxiety, and propose using the data as a basis
      for statistically powering a future R01 application. We will ask: Is Chamomile a safe and
      effective alternative treatment for Generalized Anxiety Disorder (GAD)? To do this, 60
      patients with a diagnosis of mild to moderate GAD will receive double-blind treatment for 8
      weeks with either (i) Chamomile extract, or (ii) placebo. We hypothesize that Chamomile will
      have a superior anti-anxiety efficacy compared to placebo, and a comparable safety profile to
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on Hamilton Anxiety Rating Scale</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Index Rating</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chamomile Extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Anxiolytic Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chamomile Extract</intervention_name>
    <description>220 mg - 1100 mg daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 to 5 capsules daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women &gt; 18 years of age (all races and ethnicity)

        Meet DSM IV criteria for GAD

        Mild to moderate symptom severity

        HAM-A score &gt; 8

        Not receiving anti-anxiety medication (e.g., benzodiazepine, venlafaxine, buspirone, or
        SSRI)

        Able to understand and provide signed informed consent

        Able to participate in a 8-week study

        Exclusion Criteria:

        Patients &lt; 18 years old

        Current DSM IV Axis I diagnosis of Major Depressive Disorder, Bipolar Disorder, Panic
        Disorder (with or without agoraphobia), Specific Phobia Disorder, Obsessive-Compulsive
        Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Substance-Induced Anxiety
        Disorder, Schizophrenia, Other psychotic disorders, Current alcohol or drug abuse, Alcohol
        or drug dependence within 3 months, [NB: Patients with co-morbid DSM IV Axis I Depressive
        Disorders NOS (e.g., minor depressive disorder, premenstrual dysphoric disorder, and
        recurrent brief depressive disorder will not be excluded)]

        Unstable medical condition (e.g., hypothyroidism, hypertension, myocardial infarction
        within 1 month, neoplastic condition)

        Allergy to Chamomile preparation

        Allergy to plants of the asteraceae family (e.g., ragweed, asters, chrysanthemum)

        Allergy to mugwort, RAST, or birch tree pollen

        Concurrent tranquilizer, antidepressant or mood stabilizer therapy

        Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g.,
        Chamomile, St. John's Wort, Kava kava)

        Women of child-bearing potential not willing to employ a medically proven form of
        contraception (e.g., condoms, oral contraceptives, etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay D. Amsterdam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Research Unit, Universityof Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jay D. Amsterdam, M.D., Professor</name_title>
    <organization>University of Pennsylvania</organization>
  </responsible_party>
  <keyword>Chamomile</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Complementary and Alternative Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

